MYOG Myogen

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of darusentan on resistant hypertension has been selected for oral presentation at the American Heart Association Scientific Sessions conference to be held Nov. 12-15, 2006, at the McCormick Place Convention Center in Chicago, Ill. Michael Weber, M.D., will present �Darusentan Significantly Reduces Systolic Blood Pressure in Patients with Resistant Hypertension on Four or More Antihypertensive Drugs.� The presentation is scheduled for Monday, Nov. 13, 2006, from 2:15 p.m. to 2:30 p.m. Dr. Weber is an Associate Dean and Professor of Medicine at the State University of New York Health Science Center in Brooklyn, N.Y., and is a member of the clinical advisory group for the darusentan development program. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension. Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan� (epoprostenol sodium) for injection in the United States and GlaxoSmithKline has licensed ambrisentan from Myogen for all territories outside of the United States, where Myogen retains exclusive rights. Myogen also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com. Safe Harbor Statement The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the �Risk Factors� section of Myogen�s Form 10-K for the year ended December 31, 2005 and Myogen�s periodic reports on Form 10-Q and Form 8-K. Results from clinical trials, including the Company's Darusentan Phase 2b trial, are not necessarily predictive of future clinical results. Myogen does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of darusentan on resistant hypertension has been selected for oral presentation at the American Heart Association Scientific Sessions conference to be held Nov. 12-15, 2006, at the McCormick Place Convention Center in Chicago, Ill. Michael Weber, M.D., will present "Darusentan Significantly Reduces Systolic Blood Pressure in Patients with Resistant Hypertension on Four or More Antihypertensive Drugs." The presentation is scheduled for Monday, Nov. 13, 2006, from 2:15 p.m. to 2:30 p.m. Dr. Weber is an Associate Dean and Professor of Medicine at the State University of New York Health Science Center in Brooklyn, N.Y., and is a member of the clinical advisory group for the darusentan development program. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension. Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for injection in the United States and GlaxoSmithKline has licensed ambrisentan from Myogen for all territories outside of the United States, where Myogen retains exclusive rights. Myogen also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com. Safe Harbor Statement The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended December 31, 2005 and Myogen's periodic reports on Form 10-Q and Form 8-K. Results from clinical trials, including the Company's Darusentan Phase 2b trial, are not necessarily predictive of future clinical results. Myogen does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.